The 2025 EHA Congress took place in Milan, Italy, from June 12–15. Many representatives from CML AN joined the event and actively participated in the diverse sessions, meetings, and activities on offer. It was an intense and inspiring four days, filled with lots of learning.
We are excited to now share a new initiative: a concise summary in the form of a Podcast of the two CML sessions held during the Congress:
- Session 425: Clinical Novel approaches of CML treatment, with Andreas Hochhaus explaining the “ENABLE Phase 1A/1B study of ELVN-001” and “Asciminib tolerability superiority vs nilotinib in newly diagnosed CML”, “Treatment discontinuation after a 2-step dose reduction” by Jiri Mayer, “Comparison of molecular response and safety of lower dose vs standard of generic Dasatinib in newly diagnosed CML patients” by Paras Satadeve, and “the characterization and efficacy of TERN-701 in pre-clinical models of CML” by Timothy Hughes.
- Session 120: This session was chaired by our Co-Founder Giora Sharf and talks about “BCR-ABL1 kinase domain mutations associated with asciminib”, and “Sequencing TKI for optimal management of CML”
The 2 podcasts were created by Google Notebook LM, a new adventure we are embarking on using AI tools which summaries the sessions in an interesting and informative way. Feel free to listen to the audio files here:
